stockrowAbbott Laboratories
ABT Healthcare Medical Devices
Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024.
- Revenue
- +14.5%
- EPS
- −43.6%
- Free cash flow
- +28.9%
- Total debt
- +142.7%
Quarter to September 2026, against a year earlier
Follow ABT
Alert me
Abbott Laboratories (ABT) Shares outstanding
Abbott Laboratories's shares outstanding at the end of fiscal 2025 was $1.7B, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $1.7B. Over the past ten years it has ranged from $1.5B (fiscal 2016) to $1.8B (fiscal 2021); the current reading is higher than 36% of that period. Abbott Laboratories ranks 1st of 147 Medical Devices companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $1.7B | 0.00% |
| FY2024 | $1.7B | (0.06%) |
| FY2023 | $1.7B | (0.85%) |
| FY2022 | $1.8B | (1.40%) |
| FY2021 | $1.8B | 0.17% |
| FY2020 | $1.8B | 0.28% |
| FY2019 | $1.8B | 0.62% |
| FY2018 | $1.8B | 1.20% |
| FY2017 | $1.7B | 17.94% |
| FY2016 | $1.5B | (1.53%) |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $1.7B | (0.29%) |
| Jun 2026 | $1.7B | (0.23%) |
| Mar 2026 | $1.7B | (0.05%) |
| Dec 2025 | $1.7B | (0.08%) |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ABT Abbott Laboratories | $1.7B |
| BSX Boston Scientific Corporation compare | $1.5B |
| MDT Medtronic PLC compare | $1.3B |
| PHG Koninklijke Philips N.V. compare | $989.9M |
| EW Edwards Lifesciences Corporation compare | $577.6M |
| GEHC GE HealthCare Technologies Inc. compare | $453.0M |
| SYK Stryker Corporation compare | $384.7M |
| DXCM DexCom, Inc. compare | $383.5M |
| STE STERIS plc compare | $97.6M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on ABT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement